A $1B Acquisition Gives Novartis a Way to Stand Out in Crowded Area of Cancer
Frank Vinluan / medcitynews - Myricx Bio brings to Novartis antibody drug conjugates with a novel cancer-killing payload called an NMT inhibitor. Novartis says Myricx’s drugs could have advantages over currently available ADCs as well as those still in clinical development. The post A…
AI Summary: Novartis has struck a roughly $1 billion deal to acquire Myricx Bio, a preclinical bet aimed at securing a novel antibody‑drug conjugate payload. The move is a clear attempt to stand out in a crowded oncology market by buying potential innovation rather than inventing it in‑house — or, as finance folks call it, buying optionality.
IKS Health completes $557M TruBridge acquisition
Andrew Cass / beckershospitalreview - IKS Health has completed its $557 million acquisition of TruBridge, which provides revenue cycle management and EHR services for rural and community hospitals. Following the closing, TruBridge operates as a wholly owned subsidiary of IKS Health, according…
AI Summary: IKS Health has closed a $557 million deal to acquire TruBridge, integrating the acquired firm’s revenue-cycle and IT capabilities into IKS’s technology stack. The purchase accelerates IKS’s push to expand managed services for health systems, promising greater scale and product consolidation—because nothing says progress like buying your way into the future.